SCHEMBL3207646

SCHEMBL3207646

CN(C)c1cc2ccccn2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 1/20 0.46
ABL1 P00519 1/20 0.46
MAPK8 P45983 1/20 0.46
CSNK1A1 P48729 1/20 0.46
CDK7 P50613 1/20 0.46
TYRO3 Q06418 1/20 0.46
LRRK2 Q5S007 1/20 0.46
AURKB Q96GD4 1/20 0.46
CLK4 Q9HAZ1 1/20 0.46
PIM2 Q9P1W9 1/20 0.46
DYRK1B Q9Y463 1/20 0.46
MAP3K5 Q99683 1/20 0.41
NPC1 O15118 5/20 0.40
RAB9A P51151 5/20 0.40
TP53 P04637 9/20 0.39
MAPT P10636 5/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
PKM P14618 1/20 0.38
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31030380 0.81 MAP4K4 (0.37) MAP4K4ABL1MAPK8CSNK1A1CDK7
SCHEMBL11662811 0.80 MAP4K4 (0.43) MAP4K4ABL1MAPK8CSNK1A1CDK7
SCHEMBL21388302 0.80 MAP4K4 (0.40) MAP4K4ABL1MAPK8CSNK1A1CDK7
SCHEMBL434570 0.74 MAP4K4 (0.54) MAP4K4ABL1MAPK8CSNK1A1CDK7
SCHEMBL651412 0.71 MAP4K4 (0.47) MAP4K4ABL1MAPK8CSNK1A1CDK7
SCHEMBL10129496 0.71 MAP4K4 (0.47) MAP4K4ABL1MAPK8CSNK1A1CDK7
SCHEMBL23535657 0.69 NPC1 (0.46) MAP4K4ABL1MAPK8CSNK1A1CDK7
SCHEMBL13569111 0.69 MAP4K4 (0.46) MAP4K4ABL1MAPK8CSNK1A1CDK7
SCHEMBL1269053 0.69 MAP4K4 (0.50) MAP4K4ABL1MAPK8CSNK1A1CDK7
SCHEMBL14809152 0.69 MAP4K4 (0.46) MAP4K4ABL1MAPK8CSNK1A1CDK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100035920-A1 SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE AVIGEN, INC. (US) 2010-02-11 US disclosed
US-20090318437-A1 SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE MEDICINOVA, INC. 2009-12-24 US disclosed
US-7585875-B2 Substituted pyrazolo[1,5-a]pyridine compounds and their methods of use AVIGEN, INC. (US) 2009-09-08 US disclosed
EP-2038279-A2 SUBSTITUTED PYRAZOLO [1,5- ALPHA] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE Avigen, Inc. (US) 2009-03-25 EP disclosed
WO-2007146087-A2 SUBSTITUTED PYRAZOLO [1,5-α] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE AVIGEN, INC. (US) 2007-12-21 WO disclosed
US-4097483-A HYPOTENSIVE AND ANTISPASMODIC AGENT KYORIN PHARMACEUTICAL CO., LTD. (JA) 1978-06-27 US disclosed
US-4028370-A SMOOTH MUSCLE RELAXANTS, CEREBRAL AND CORONARY DILATORS, HYPOTENSIVE AGENTS KYORIN PHARMACEUTICAL CO., LTD. (JA) 1977-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318437-A1 SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE PNPO, PDXK, CYP3A5 MAP4K4 256/4885ABL1 114/4885MAPK8 1126/4885
US-20100035920-A1 SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE PNPO, PDXK, CYP3A5 MAP4K4 256/4885ABL1 114/4885MAPK8 1126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.